英国における製薬業界の市場

Report Scope

The UK pharmaceutical market and industry is analysed in this report, covering prescription medicines, and over the counter products. Market trends are fully detailed, including appraisal of demographic factors, expenditure trends, generic activity and outsourcing.

The report contains five year historical data, current market conditions and influences, together with a five year sector forecast by MBD analysts. The data is clearly presented and illustrated.

Table of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

• 2.1 Definitions
• 2.2 Abbreviations
• 2.3 Market Positioning
• 2.4 UK Economy
• 2.5 Market Factors

3. MARKET SIZE AND TRENDS

• 3.1 Chapter Summary
• 3.2 Market Size
• 3.3 Market Segmentation
  • 3.3.1 Prescription Medicines
  • 3.3.2 OTC Medicines
• 3.4 Market Trends
  • 3.4.1 Demographics
  • 3.4.2 Expenditure
  • 3.4.3 Generics
  • 3.4.4 Outsourcing
  • 3.4.5 Parallel Trade
  • 3.4.6 Herbal Medicines

4. SUPPLY SOURCES

• 4.1 Chapter Summary
• 4.2 Production
  • 4.2.1 Overview
  • 4.2.2 Segmentation
• 4.3 Imports
  • 4.3.1 Overview
  • 4.3.2 Segmentation
• 4.4 Exports
  • 4.4.1 Overview
  • 4.4.2 Segmentation
• 4.5 Trade Surplus/Deficit

5. INDUSTRY STRUCTURE

• 5.1 Chapter Summary
• 5.2 Industry Development
• 5.3 Structure by Employment
• 5.4 Structure by Turnover
• 5.5 Company Profiles
  • 5.5.1 American Home Products Holdings (UK)
  • 5.5.2 Amersham
  • 5.5.3 AstraZeneca
  • 5.5.4 Bristol-Myers Squibb Pharmaceuticals
  • 5.5.5 Celltech Group
  • 5.5.6 Eli Lilly & Co
  • 5.5.7 GlaxoSmithKline
  • 5.5.8 Johnson & Johnson
  • 5.5.9 Merck
  • 5.5.10 Merial
  • 5.5.11 Novartis UK
  • 5.5.12 Pfizer
  • 5.5.13 Pharmacia
  • 5.5.14 Roche Products
  • 5.5.15 Shire Pharmaceuticals Group
  • 5.5.16 Unichem

6. FORECAST

• 6.1 Chapter Summary
• 6.2 Market Size
• 6.3 Market Segmentation
• 6.4 Production
• 6.5 Imports
• 6.6 Industry

7. FURTHER SOURCES & CONTACTS

• 7.1 Trade Associations
• 7.2 Trade Magazines
• 7.3 Trade Exhibitions

List of Tables

• 1: UK Market for Pharmaceutical Products, 1998-2002
• 2: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002
• 3: Segmentation of the UK Market for Pharmaceutical Products, 1998-2002
• 4: Number of Prescription Items Dispensed in the UK Market, by Country, 1997-2001
• 5: Prescription Items Dispensed in the UK Market, by Disease, 2001
• 6: UK Market for OTC Pharmaceutical Products and Top Branded Sellers, by Therapeutic Category, 2002
• 7: UK Population, by Age Group, 1981-2021
• 8: NHS Expenditure on Medicines in the UK, 1998-2002
• 9: UK Production of Pharmaceutical Products, 1998-2002
• 10: Segmentation of the UK Production of Pharmaceutical Products, by Type, 1998-2002
• 11: UK Imports of Pharmaceutical Products, 1998-2002
• 12: Segmentation of UK Imports of Pharmaceutical Products, by Type, 1998-2002
• 13: UK Exports of Pharmaceutical Products, 1998-2002
• 14: Segmentation of UK Exports of Pharmaceutical Products, by Type, 1998-2002
• 15: Analysis of the Changes in the Structure of the Basic Pharmaceuticals Manufacturing Industry, 1998-2002
• 16: Analysis of the Changes in the Structure of the Pharmaceutical Preparations Manufacturing Industry, 1998-2002
• 17: Analysis of the Employment Structure of the Basic Pharmaceuticals Manufacturing Industry, 2001 and 2002
• 18: Analysis of the Employment Structure of the Pharmaceutical Preparations Manufacturing Industry, 2001 and 2002
• 19: Analysis of the Financial Structure of the Basic Pharmaceuticals Manufacturing Sector, 2001 and 2002
• 20: Analysis of the Financial Structure of the Pharmaceutical Preparations Manufacturing Sector, 2001 and 2002
• 21: Financial Analysis of American Home Products Holdings (UK), 1997-2001
• 22: Key Financial Ratios for American Home Products Holdings (UK), 2000-2001
• 23: Financial Analysis of Amersham, 1997-2001
• 24: Key Financial Ratios for Amersham, 2000-2001
• 25: Financial Analysis of AstraZeneca, 1997-2001
• 26: Key Financial Ratios for AstraZeneca, 2000-2001
• 27: Financial Analysis of Bristol-Myers Squibb Pharmaceuticals, 1997-2001
• 28: Key Financial Ratios for Bristol-Myers Squibb Pharmaceuticals, 2000-2001
• 29: Financial Analysis of Celltech Group, 1997-2001
• 30: Key Financial Ratios for Celltech Group, 2000-2001
• 31: Financial Analysis of Eli Lilly & Company, 1997-2001
• 32: Key Financial Ratios for Eli Lilly & Co, 2000-2001
• 33: Financial Analysis of GlaxoSmithKline, 2000-2001
• 34: Key Financial Ratios for GlaxoSmithKline, 2000-2001
• 35: Financial Analysis of Johnson & Johnson, 1997-2001
• 36: Key Financial Ratios for Johnson & Johnson, 2000-2001
• 37: Financial Analysis of Merck, 1997-2001
• 38: Analysis of Merck Turnover, by Activity, 1997-2001
• 39: Key Financial Ratios for Merck, 2000-2001
• 40: Financial Analysis of Merial, 1997-2001
• 41: Key Financial Ratios for Merial, 2000-2001
• 42: Financial Analysis of Novartis UK, 1997-2001
• 43: Key Financial Ratios for Novartis UK, 2000-2001
• 44: Financial Analysis of Pfizer, 1997-2001
• 45: Key Financial Ratios for Pfizer, 2000-2001
• 46: Financial Analysis of Pharmacia, 1997-2001
• 47: Key Financial Ratios for Pharmacia, 2000-2001
• 48: Financial Analysis of Roche Products, 1997-2001
• 49: Key Financial Ratios for Roche Products, 2000-2001
• 50: Financial Analysis of Shire Pharmaceuticals Group, 1997-2001
• 51: Key Financial Ratios for Shire Pharmaceuticals Group, 2000-2001
• 52: Financial Analysis of Unichem, 1999-2001
• 53: Key Financial Ratios for Unichem, 2000-2001
• 54: Forecast UK Market for Pharmaceutical Products, 2003-2007
• 55: Forecast Segmentation of the UK Market for Pharmaceutical Products, 2003-2007
• 56: Forecast UK Production of Pharmaceutical Products, 2003-2007
• 57: Forecast UK Imports of Pharmaceutical Products, 2003-2007